{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T12:35:09Z","timestamp":1719405309401},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,9]]},"DOI":"10.7759\/cureus.38772","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T16:24:22Z","timestamp":1683649462000},"source":"Crossref","is-referenced-by-count":2,"title":["A Review of Pityriasis Rosea in Relation to SARS-CoV-2\/COVID-19 Infection and Vaccination"],"prefix":"10.7759","author":[{"given":"Nikita","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla A","family":"Cascardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey  A","family":"Potts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17498","article-title":"Pityriasis rosea developing after COVID-19 vaccination","volume":"35","author":"Marcantonio-Santa Cruz OY","year":"2021","unstructured":"Marcantonio-Santa Cruz OY, Vidal-Navarro A, Pesqu\u00e9 D, Gim\u00e9nez-Arnau AM, Pujol RM, Martin-Ezquerra G. Pityriasis rosea developing after COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2021, 35:e721-2. 10.1111\/jdv.17498","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5233","article-title":"Pityriasis rosea","volume":"351","author":"Eisman S","year":"2015","unstructured":"Eisman S, Sinclair R. Pityriasis rosea. BMJ. 2015, 351:h5233. 10.1136\/bmj.h5233","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17744","article-title":"Cutaneous findings following COVID-19 vaccination: review of world literature and own experience","volume":"36","author":"Gambichler T","year":"2022","unstructured":"Gambichler T, Boms S, Susok L, et al.. Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. J Eur Acad Dermatol Venereol. 2022, 36:172-80. 10.1111\/jdv.17744","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15700","article-title":"Pityriasis rosea after mRNA COVID-19 vaccination","volume":"60","author":"Abdullah L","year":"2021","unstructured":"Abdullah L, Hasbani D, Kurban M, Abbas O. Pityriasis rosea after mRNA COVID-19 vaccination. Int J Dermatol. 2021, 60:1150-1. 10.1111\/ijd.15700","journal-title":"Int J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15040","article-title":"Post Covid-19 vaccination papulovesicular pityriasis rosea-like eruption in a young male","volume":"34","author":"Adya KA","year":"2021","unstructured":"Adya KA, Inamadar AC, Albadri W. Post Covid-19 vaccination papulovesicular pityriasis rosea-like eruption in a young male. Dermatol Ther. 2021, 34:e15040. 10.1111\/dth.15040","journal-title":"Dermatol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17316","article-title":"Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report","volume":"35","author":"Akda\u015f E","year":"2021","unstructured":"Akda\u015f E, \u0130lter N, \u00d6\u011f\u00fct B, Erdem \u00d6. Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report. J Eur Acad Dermatol Venereol. 2021, 35:e491-3. 10.1111\/jdv.17316","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025352","article-title":"Pityriasis rosea Gibert triggered by SARS-CoV-2 infection: a case report","volume":"100","author":"Birlutiu V","year":"2021","unstructured":"Birlutiu V, Birlutiu RM, Iancu GM. Pityriasis rosea Gibert triggered by SARS-CoV-2 infection: a case report. Medicine (Baltimore). 2021, 100:e25352. 10.1097\/MD.0000000000025352","journal-title":"Medicine (Baltimore)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27364","article-title":"Atypical pityriasis rosea associated with mRNA COVID-19 vaccine","volume":"94","author":"Bostan E","year":"2022","unstructured":"Bostan E, Jarbou A. Atypical pityriasis rosea associated with mRNA COVID-19 vaccine. J Med Virol. 2022, 94:814-6. 10.1002\/jmv.27364","journal-title":"J Med Virol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17301","article-title":"Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance","volume":"35","author":"Busto-Leis JM","year":"2021","unstructured":"Busto-Leis JM, Servera-Negre G, Mayor-Ibarguren A, et al.. Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance. J Eur Acad Dermatol Venereol. 2021, 35:e489-91. 10.1111\/jdv.17301","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20143","article-title":"Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination","volume":"185","author":"Carballido V\u00e1zquez AM","year":"2021","unstructured":"Carballido V\u00e1zquez AM, Morgado B. Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination. Br J Dermatol. 2021, 185:e34. 10.1111\/bjd.20143","journal-title":"Br J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20639","article-title":"Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases","volume":"186","author":"Catal\u00e0 A","year":"2022","unstructured":"Catal\u00e0 A, Mu\u00f1oz-Santos C, Galv\u00e1n-Casas C, et al.. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2022, 186:142-52. 10.1111\/bjd.20639","journal-title":"Br J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1963173","article-title":"Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine","volume":"17","author":"Cohen OG","year":"2021","unstructured":"Cohen OG, Clark AK, Milbar H, Tarlow M. Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine. Hum Vaccin Immunother. 2021, 17:4097-8. 10.1080\/21645515.2021.1963173","journal-title":"Hum Vaccin Immunother"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17342","article-title":"Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 vaccine","volume":"35","author":"Cyrenne BM","year":"2021","unstructured":"Cyrenne BM, Al-Mohammedi F, DeKoven JG, Alhusayen R. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021, 35:e546-8. 10.1111\/jdv.17342","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0257","article-title":"Pityriasis rosea as a possible complication of vaccination against COVID-19","volume":"118","author":"Dormann H","year":"2021","unstructured":"Dormann H, Grummt S, Karg M. Pityriasis rosea as a possible complication of vaccination against COVID-19. Dtsch Arztebl Int. 2021, 118:431. 10.3238\/arztebl.m2021.0257","journal-title":"Dtsch Arztebl Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26549","article-title":"Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19","volume":"93","author":"Drago F","year":"2021","unstructured":"Drago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. J Med Virol. 2021, 93:1850-1. 10.1002\/jmv.26549","journal-title":"J Med Virol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16579","article-title":"Pityriasis rosea as a cutaneous manifestation of COVID-19 infection","volume":"34","author":"Ehsani AH","year":"2020","unstructured":"Ehsani AH, Nasimi M, Bigdelo Z. Pityriasis rosea as a cutaneous manifestation of COVID-19 infection. J Eur Acad Dermatol Venereol. 2020, 34:e436-7. 10.1111\/jdv.16579","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15256","article-title":"Pityriasis rosea like eruption: a dermatological manifestation of Coronavac-COVID-19 vaccine","volume":"35","author":"G\u00f6k\u00e7ek GE","year":"2022","unstructured":"G\u00f6k\u00e7ek GE, \u00d6ks\u00fcm Solak E, \u00c7\u00f6lge\u00e7en E. Pityriasis rosea like eruption: a dermatological manifestation of Coronavac-COVID-19 vaccine. Dermatol Ther. 2022, 35:e15256. 10.1111\/dth.15256","journal-title":"Dermatol Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17648","article-title":"Two cases of pityriasis rosea after the injection of coronavirus disease 2019 vaccine","volume":"36","author":"Huang L","year":"2022","unstructured":"Huang L, Yao Z, Zhang J. Two cases of pityriasis rosea after the injection of coronavirus disease 2019 vaccine. J Eur Acad Dermatol Venereol. 2022, 36:e9-e11. 10.1111\/jdv.17648","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.10.035","article-title":"Pityriasis rosea in otherwise asymptomatic confirmed COVID-19-positive patients: a report of 2 cases","volume":"7","author":"Johansen M","year":"2021","unstructured":"Johansen M, Chisolm SS, Aspey LD, Brahmbhatt M. Pityriasis rosea in otherwise asymptomatic confirmed COVID-19-positive patients: a report of 2 cases. JAAD Case Rep. 2021, 7:93-4. 10.1016\/j.jdcr.2020.10.035","journal-title":"JAAD Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.752443","article-title":"Case report: pityriasis rosea-like eruption following COVID-19 vaccination","volume":"8","author":"Leerunyakul K","year":"2021","unstructured":"Leerunyakul K, Pakornphadungsit K, Suchonwanit P. Case report: pityriasis rosea-like eruption following COVID-19 vaccination. Front Med (Lausanne). 2021, 8:752443. 10.3389\/fmed.2021.752443","journal-title":"Front Med (Lausanne)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2021.07.011","article-title":"The histologic and molecular correlates of COVID-19 vaccine-induced changes in the skin","volume":"39","author":"Magro C","year":"2021","unstructured":"Magro C, Crowson AN, Franks L, Schaffer PR, Whelan P, Nuovo G. The histologic and molecular correlates of COVID-19 vaccine-induced changes in the skin. Clin Dermatol. 2021, 39:966-84. 10.1016\/j.clindermatol.2021.07.011","journal-title":"Clin Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcle.2020.05.017","article-title":"Pityriasis rosea Gibert type rash in an asymptomatic patient that tested positive for COVID-19","volume":"155","author":"Mart\u00edn Enguix D","year":"2020","unstructured":"Mart\u00edn Enguix D, Salazar Nievas MD, Mart\u00edn Romero DT. Pityriasis rosea Gibert type rash in an asymptomatic patient that tested positive for COVID-19. Med Clin (Engl Ed). 2020, 155:273. 10.1016\/j.medcle.2020.05.017","journal-title":"Med Clin (Engl Ed)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27535","article-title":"Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies?","volume":"94","author":"Martora F","year":"2022","unstructured":"Martora F, Picone V, Fornaro L, Fabbrocini G, Marasca C. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies?. J Med Virol. 2022, 94:1292-3. 10.1002\/jmv.27535","journal-title":"J Med Virol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17678","article-title":"Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford-AstraZeneca COVID-19 vaccine: report of three cases from India","volume":"36","author":"Mehta H","year":"2022","unstructured":"Mehta H, Handa S, Malhotra P, et al.. Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford-AstraZeneca COVID-19 vaccine: report of three cases from India. J Eur Acad Dermatol Venereol. 2022, 36:e16-8. 10.1111\/jdv.17678","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17052","article-title":"Pityriasis rosea as a leading manifestation of COVID-19 infection","volume":"35","author":"Merhy R","year":"2021","unstructured":"Merhy R, Sarkis AS, Stephan F. Pityriasis rosea as a leading manifestation of COVID-19 infection. J Eur Acad Dermatol Venereol. 2021, 35:e246-7. 10.1111\/jdv.17052","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_127_21","article-title":"An observational study of mucocutaneous manifestations among SARS-CoV-2 patients from three COVID-19 dedicated tertiary care centers","volume":"12","author":"Mohta A","year":"2021","unstructured":"Mohta A, Mohta A, Nai RS, et al.. An observational study of mucocutaneous manifestations among SARS-CoV-2 patients from three COVID-19 dedicated tertiary care centers. Indian Dermatol Online J. 2021, 12:687-95. 10.4103\/idoj.IDOJ_127_21","journal-title":"Indian Dermatol Online J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2021.07.006","article-title":"Pityriasis rosea in a confirmed COVID-19 pediatric patient","volume":"112","author":"\u00d6nc\u00fc IN","year":"2021","unstructured":"\u00d6nc\u00fc IN, G\u00fcler D, G\u00fcrel G, Yal\u00e7\u0131n G\u015e. Pityriasis rosea in a confirmed COVID-19 pediatric patient. Actas Dermosifiliogr. 2021, 112:864-5. 10.1016\/j.adengl.2021.07.006","journal-title":"Actas Dermosifiliogr"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14972","article-title":"Pityriasis rosea infection in a COVID-19 patient successfully treated with systemic steroid and antihistamine via telemedicine: literature update of a possible prodromal symptom of an underlying SARS-CoV-2 infection","volume":"34","author":"Paolino G","year":"2021","unstructured":"Paolino G, Di Nicola MR, Cantisani C, Mercuri SR. Pityriasis rosea infection in a COVID-19 patient successfully treated with systemic steroid and antihistamine via telemedicine: literature update of a possible prodromal symptom of an underlying SARS-CoV-2 infection. Dermatol Ther. 2021, 34:e14972. 10.1111\/dth.14972","journal-title":"Dermatol Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15129","article-title":"Pityriasis rosea-like cutaneous eruption as a possible dermatological manifestation after Oxford-AstraZeneca vaccine: case report and brief literature review","volume":"34","author":"Pedrazini MC","year":"2021","unstructured":"Pedrazini MC, da Silva MH. Pityriasis rosea-like cutaneous eruption as a possible dermatological manifestation after Oxford-AstraZeneca vaccine: case report and brief literature review. Dermatol Ther. 2021, 34:e15129. 10.1111\/dth.15129","journal-title":"Dermatol Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17409","article-title":"Contemporary occurrence of Chilblain-like lesions and pityriasis rosea during the COVID-19 pandemic","volume":"35","author":"Piccolo V","year":"2021","unstructured":"Piccolo V, Bassi A, Argenziano G, et al.. Contemporary occurrence of Chilblain-like lesions and pityriasis rosea during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2021, 35:e619-20. 10.1111\/jdv.17409","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.10.055","article-title":"Pityriasis rosea shortly after mRNA-1273 COVID-19 vaccination","volume":"114","author":"Shin SH","year":"2022","unstructured":"Shin SH, Hong JK, Hong SA, Li K, Yoo KH. Pityriasis rosea shortly after mRNA-1273 COVID-19 vaccination. Int J Infect Dis. 2022, 114:88-9. 10.1016\/j.ijid.2021.10.055","journal-title":"Int J Infect Dis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14372","article-title":"Pityriasis rosea following SARS-CoV-2 vaccination: a case series","volume":"20","author":"Temiz SA","year":"2021","unstructured":"Temiz SA, Abdelmaksoud A, Dursun R, Durmaz K, Sadoughifar R, Hasan A. Pityriasis rosea following SARS-CoV-2 vaccination: a case series. J Cosmet Dermatol. 2021, 20:3080-4. 10.1111\/jocd.14372","journal-title":"J Cosmet Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13504","article-title":"Pityriasis rosea-like eruption revealing COVID-19","volume":"62","author":"Veraldi S","year":"2021","unstructured":"Veraldi S, Romagnuolo M, Benzecry V. Pityriasis rosea-like eruption revealing COVID-19. Australas J Dermatol. 2021, 62:e333-4. 10.1111\/ajd.13504","journal-title":"Australas J Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26679","article-title":"Pityriasis rosea and COVID-19","volume":"93","author":"Veraldi S","year":"2021","unstructured":"Veraldi S, Spigariolo CB. Pityriasis rosea and COVID-19. J Med Virol. 2021, 93:4068. 10.1002\/jmv.26679","journal-title":"J Med Virol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2021.12.028","article-title":"Pityriasis rosea-like eruptions following COVID-19 mRNA-1273 vaccination: a case report and literature review","volume":"121","author":"Wang CS","year":"2022","unstructured":"Wang CS, Chen HH, Liu SH. Pityriasis rosea-like eruptions following COVID-19 mRNA-1273 vaccination: a case report and literature review. J Formos Med Assoc. 2022, 121:1003-7. 10.1016\/j.jfma.2021.12.028","journal-title":"J Formos Med Assoc"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19833","article-title":"SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19","volume":"184","author":"Welsh E","year":"2021","unstructured":"Welsh E, Cardenas-de la Garza JA, Cuellar-Barboza A, Franco-Marquez R, Arvizu-Rivera RI. SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19. Br J Dermatol. 2021, 184:1194-5. 10.1111\/bjd.19833","journal-title":"Br J Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23719.x","article-title":"Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7","volume":"124","author":"Broccolo F","year":"2005","unstructured":"Broccolo F, Drago F, Careddu AM, et al.. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol. 2005, 124:1234-40. 10.1111\/j.0022-202X.2005.23719.x","journal-title":"J Invest Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.3290","article-title":"Pityriasis rosea","volume":"154","author":"Schadt C","year":"2018","unstructured":"Schadt C. Pityriasis rosea. JAMA Dermatol. 2018, 154:1496. 10.1001\/jamadermatol.2018.3290","journal-title":"JAMA Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/132761-a-review-of-pityriasis-rosea-in-relation-to-sars-cov-2covid-19-infection-and-vaccination","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:58:31Z","timestamp":1707508711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/132761-a-review-of-pityriasis-rosea-in-relation-to-sars-cov-2covid-19-infection-and-vaccination"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.38772","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,9]]}}}